Related Experiment Video

Updated: Feb 16, 2026

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

2.6K

FLT3 inhibitors in acute myeloid leukemia: Choosing the best when the optimal does not exist

Rita Assi1, Farhad Ravandi1

  • 1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

American Journal of Hematology
|December 30, 2017
PubMed

Insights

Novel FLT3 inhibitors show promise for acute myeloid leukemia (AML) treatment, but resistance remains a challenge. This review explores FLT3 inhibitor development, resistance mechanisms, and strategies for future clinical trials.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Acute myeloid leukemia (AML) treatment outcomes have seen limited improvement despite advances in understanding its molecular pathways.
  • The FMS-like tyrosine kinase 3 (FLT3) pathway is implicated in leukemogenesis, presenting a promising therapeutic target.
  • First-generation FLT3 inhibitors faced setbacks, but newer agents demonstrate potent activity and improved pharmacodynamics.

Purpose of the Study:

  • To review the development of FLT3 inhibitors for AML.
  • To explore the molecular pathways contributing to FLT3 inhibitor resistance.
  • To summarize strategies for designing improved clinical trials to overcome treatment failure.

Main Methods:

  • Literature review of FLT3 inhibitor development in AML.
  • Analysis of molecular mechanisms underlying resistance to FLT3-targeted therapies.
  • Synthesis of data on novel FLT3 inhibitors and combination strategies.

Main Results:

  • Despite promising results from novel FLT3 inhibitors, AML remains challenging due to rapid resistance.
  • Understanding resistance pathways is crucial for effective therapeutic strategies.
  • Optimizing FLT3 inhibitor selection and combination therapies is essential for improved clinical outcomes.

Conclusions:

  • FLT3 inhibitors represent a significant advancement in AML therapy, but overcoming resistance is paramount.
  • Further research into resistance mechanisms and molecularly-designed clinical trials are needed.
  • Personalized treatment strategies incorporating optimal FLT3 inhibitors and combinations hold potential for future success.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

976

Related Concept Videos

Choosing Between z and t Distribution01:25

Choosing Between z and t Distribution

The z and the Student t distribution estimate the population mean using the sample mean and standard deviation. However, to decide which distribution to use for a calculation, one needs to determine the sample size, the nature of the distribution, and whether the population standard deviation is known. If the population standard deviation is known and the population is normally distributed, or if the sample size is greater than 30, the z distribution is preferred. The Student t distribution is...
3.7K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.1K
Optimal Foraging00:48

Optimal Foraging

How animals obtain and eat their food is called foraging behavior. Foraging can include searching for plants and hunting for prey and depends on the species and environment.
14.0K
Optimization Problems01:26

Optimization Problems

Optimization problems often involve identifying maximum or minimum values under specific constraints. A well-known example is determining the longest horizontal pipe that can be moved around a right-angled corner, where a 3-meter-wide hallway meets a 2-meter-wide hallway. This scenario, common in architectural design and industrial transport, can be understood conceptually through geometric and trigonometric reasoning.To visualize the problem, consider the pipe as a straight line that touches...
85
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.1K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
718